Cancer NetworkOriginal article
<![CDATA[IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma]]>
RegulatoryapprovedIASO208Positive
AI Analysis
Summary
IASO208, a CD20-targeted in vivo CAR-T therapy, received FDA IND clearance for relapsed/refractory B-cell lymphoma, enabling advancement to phase 1b testing. The therapy requires no leukapheresis or lymphodepletion.
Clinical Trial Data
Phase
1b
Outcome Details
FDA IND clearance granted
Importance:6/10
Sentiment:
0.80
CAR-TCD20-targetedIND clearanceB-cell lymphomain vivo therapy
Read the original article
Published by Cancer Network on September 16, 2026 4:00 PM